Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, García A, Gener P, Mina L, Alcalá-López D, Sampayo M, Cortés J, Pérez-Garcia JM, Llombart-Cussac A, López-Miranda E.
López González A, et al. Among authors: lopez miranda e, gonzalez x.
Cancers (Basel). 2022 Nov 29;14(23):5880. doi: 10.3390/cancers14235880.
Cancers (Basel). 2022.
PMID: 36497361
Free PMC article.